Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA. The biotech has ...

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

As of 11:07:41 AM EDT. Market Open.

Xtrackers S&P 500 Swap UCITS ETF - 1C USD ACC 23% SPDR S&P 500 UCITS ETF - USD DIS 23% ...